Chardan Capital Keeps Their Buy Rating on Spring Bank Pharmaceuticals Inc (SBPH)


In a report released today, Taylor Feehley from Chardan Capital reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (SBPH), with a price target of $45. The company’s shares closed yesterday at $11.15.

Currently, the analyst consensus on Spring Bank Pharmaceuticals Inc is a Strong Buy with an average price target of $30.67.

See today’s analyst top recommended stocks >>

Based on Spring Bank Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.78 million. In comparison, last year the company had a GAAP net loss of $10.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists platforms. The company was founded by Douglas J. Jensen and Radhakrishnan P.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts